Long-term Clinical Morbidity in Patients With Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex

John Bissler, Katherine Cappell, Hearns Charles, Xue Song, Zhimei Liu, Judith Prestifilippo, Christopher Gregory, John Hulbert

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective To estimate the incidence rates of kidney-related clinical outcomes among patients with tuberous sclerosis complex (TSC)-related angiomyolipoma (AML) compared to an age-matched control cohort in the United States. Materials and Methods This was a retrospective, observational study. Administrative data from the MarketScan Research Databases were used to select patients with TSC and renal AML. An age-matched group with no TSC or renal AML was identified for comparison. Outcomes were incidence rates per 100 patient-years and number of months to development of hematuria, chronic kidney disease, renal hemorrhage, kidney failure, and inpatient death. Results Among the commercially insured TSC-renal AML patients (N = 605) and matched controls (N = 1815), 37.2% were <18 years old. Among Medicaid TSC-renal AML patients (N = 246) and matched controls (N = 738), 38.6% were aged <18. In the commercial sample, in both age groups (<18 and ≥18), the incidence rate of each clinical outcome measured was higher in the TSC-renal AML cohort than in the control cohort, with several differences reaching statistical significance. Compared with younger patients, older TSC-renal AML patients had higher incidence rates of clinical outcomes (hematuria: 20.4 vs 8.7; chronic kidney disease: 9.6 vs 3.5; renal hemorrhage 2.7 vs 0.7; kidney failure: 1.9 vs 0.4) and took less time on average to develop each clinical outcome. A similar pattern of results was observed among patients with Medicaid insurance. Conclusion TSC-renal AML patients are at significantly higher risk for renal morbidity relative to the general population.

Original languageEnglish (US)
Pages (from-to)80-87
Number of pages8
JournalUrology
Volume95
DOIs
StatePublished - Sep 1 2016

Fingerprint

Angiomyolipoma
Tuberous Sclerosis
Morbidity
Kidney
Incidence
Medicaid
Hematuria
Chronic Renal Insufficiency
Renal Insufficiency
Age Groups
Hemorrhage
Insurance
Observational Studies
Inpatients
Research Design
Retrospective Studies

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Long-term Clinical Morbidity in Patients With Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex. / Bissler, John; Cappell, Katherine; Charles, Hearns; Song, Xue; Liu, Zhimei; Prestifilippo, Judith; Gregory, Christopher; Hulbert, John.

In: Urology, Vol. 95, 01.09.2016, p. 80-87.

Research output: Contribution to journalArticle

Bissler, J, Cappell, K, Charles, H, Song, X, Liu, Z, Prestifilippo, J, Gregory, C & Hulbert, J 2016, 'Long-term Clinical Morbidity in Patients With Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex', Urology, vol. 95, pp. 80-87. https://doi.org/10.1016/j.urology.2016.04.027
Bissler, John ; Cappell, Katherine ; Charles, Hearns ; Song, Xue ; Liu, Zhimei ; Prestifilippo, Judith ; Gregory, Christopher ; Hulbert, John. / Long-term Clinical Morbidity in Patients With Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex. In: Urology. 2016 ; Vol. 95. pp. 80-87.
@article{9a7e915e13204877baec07995f993666,
title = "Long-term Clinical Morbidity in Patients With Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex",
abstract = "Objective To estimate the incidence rates of kidney-related clinical outcomes among patients with tuberous sclerosis complex (TSC)-related angiomyolipoma (AML) compared to an age-matched control cohort in the United States. Materials and Methods This was a retrospective, observational study. Administrative data from the MarketScan Research Databases were used to select patients with TSC and renal AML. An age-matched group with no TSC or renal AML was identified for comparison. Outcomes were incidence rates per 100 patient-years and number of months to development of hematuria, chronic kidney disease, renal hemorrhage, kidney failure, and inpatient death. Results Among the commercially insured TSC-renal AML patients (N = 605) and matched controls (N = 1815), 37.2{\%} were <18 years old. Among Medicaid TSC-renal AML patients (N = 246) and matched controls (N = 738), 38.6{\%} were aged <18. In the commercial sample, in both age groups (<18 and ≥18), the incidence rate of each clinical outcome measured was higher in the TSC-renal AML cohort than in the control cohort, with several differences reaching statistical significance. Compared with younger patients, older TSC-renal AML patients had higher incidence rates of clinical outcomes (hematuria: 20.4 vs 8.7; chronic kidney disease: 9.6 vs 3.5; renal hemorrhage 2.7 vs 0.7; kidney failure: 1.9 vs 0.4) and took less time on average to develop each clinical outcome. A similar pattern of results was observed among patients with Medicaid insurance. Conclusion TSC-renal AML patients are at significantly higher risk for renal morbidity relative to the general population.",
author = "John Bissler and Katherine Cappell and Hearns Charles and Xue Song and Zhimei Liu and Judith Prestifilippo and Christopher Gregory and John Hulbert",
year = "2016",
month = "9",
day = "1",
doi = "10.1016/j.urology.2016.04.027",
language = "English (US)",
volume = "95",
pages = "80--87",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Long-term Clinical Morbidity in Patients With Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex

AU - Bissler, John

AU - Cappell, Katherine

AU - Charles, Hearns

AU - Song, Xue

AU - Liu, Zhimei

AU - Prestifilippo, Judith

AU - Gregory, Christopher

AU - Hulbert, John

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Objective To estimate the incidence rates of kidney-related clinical outcomes among patients with tuberous sclerosis complex (TSC)-related angiomyolipoma (AML) compared to an age-matched control cohort in the United States. Materials and Methods This was a retrospective, observational study. Administrative data from the MarketScan Research Databases were used to select patients with TSC and renal AML. An age-matched group with no TSC or renal AML was identified for comparison. Outcomes were incidence rates per 100 patient-years and number of months to development of hematuria, chronic kidney disease, renal hemorrhage, kidney failure, and inpatient death. Results Among the commercially insured TSC-renal AML patients (N = 605) and matched controls (N = 1815), 37.2% were <18 years old. Among Medicaid TSC-renal AML patients (N = 246) and matched controls (N = 738), 38.6% were aged <18. In the commercial sample, in both age groups (<18 and ≥18), the incidence rate of each clinical outcome measured was higher in the TSC-renal AML cohort than in the control cohort, with several differences reaching statistical significance. Compared with younger patients, older TSC-renal AML patients had higher incidence rates of clinical outcomes (hematuria: 20.4 vs 8.7; chronic kidney disease: 9.6 vs 3.5; renal hemorrhage 2.7 vs 0.7; kidney failure: 1.9 vs 0.4) and took less time on average to develop each clinical outcome. A similar pattern of results was observed among patients with Medicaid insurance. Conclusion TSC-renal AML patients are at significantly higher risk for renal morbidity relative to the general population.

AB - Objective To estimate the incidence rates of kidney-related clinical outcomes among patients with tuberous sclerosis complex (TSC)-related angiomyolipoma (AML) compared to an age-matched control cohort in the United States. Materials and Methods This was a retrospective, observational study. Administrative data from the MarketScan Research Databases were used to select patients with TSC and renal AML. An age-matched group with no TSC or renal AML was identified for comparison. Outcomes were incidence rates per 100 patient-years and number of months to development of hematuria, chronic kidney disease, renal hemorrhage, kidney failure, and inpatient death. Results Among the commercially insured TSC-renal AML patients (N = 605) and matched controls (N = 1815), 37.2% were <18 years old. Among Medicaid TSC-renal AML patients (N = 246) and matched controls (N = 738), 38.6% were aged <18. In the commercial sample, in both age groups (<18 and ≥18), the incidence rate of each clinical outcome measured was higher in the TSC-renal AML cohort than in the control cohort, with several differences reaching statistical significance. Compared with younger patients, older TSC-renal AML patients had higher incidence rates of clinical outcomes (hematuria: 20.4 vs 8.7; chronic kidney disease: 9.6 vs 3.5; renal hemorrhage 2.7 vs 0.7; kidney failure: 1.9 vs 0.4) and took less time on average to develop each clinical outcome. A similar pattern of results was observed among patients with Medicaid insurance. Conclusion TSC-renal AML patients are at significantly higher risk for renal morbidity relative to the general population.

UR - http://www.scopus.com/inward/record.url?scp=84969626033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969626033&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2016.04.027

DO - 10.1016/j.urology.2016.04.027

M3 - Article

C2 - 27132503

AN - SCOPUS:84969626033

VL - 95

SP - 80

EP - 87

JO - Urology

JF - Urology

SN - 0090-4295

ER -